Sarepta Therapeutics, Inc.
SRPT
$19.03
-$0.10-0.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.20% | 15.58% | 47.15% | 64.89% | 59.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.20% | 15.58% | 47.15% | 64.89% | 59.15% |
| Cost of Revenue | 52.76% | 42.89% | 17.72% | 22.62% | 2.96% |
| Gross Profit | -49.04% | -23.85% | 96.94% | 136.45% | 197.51% |
| SG&A Expenses | -17.26% | -11.86% | 0.30% | 8.72% | 13.32% |
| Depreciation & Amortization | 12.77% | 9.02% | -0.82% | 2.79% | 21.34% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.12% | 69.61% | 60.31% | 69.22% | 56.90% |
| Operating Income | 100.89% | -401.62% | -206.15% | -102.45% | -23.60% |
| Income Before Tax | 114.90% | -369.28% | -294.89% | -138.78% | -582.07% |
| Income Tax Expenses | -148.21% | -56.20% | 155.76% | 126.63% | 390.57% |
| Earnings from Continuing Operations | 126.19% | -403.27% | -322.84% | -222.54% | -1,570.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 126.19% | -403.27% | -322.84% | -222.54% | -1,570.01% |
| EBIT | 100.89% | -401.62% | -206.15% | -102.45% | -23.60% |
| EBITDA | 159.02% | -339.73% | -130.32% | -48.36% | -47.66% |
| EPS Basic | 126.43% | -388.23% | -311.23% | -221.51% | -1,881.02% |
| Normalized Basic EPS | 78.30% | -371.73% | -178.00% | -78.80% | -9.12% |
| EPS Diluted | 110.18% | -401.69% | -332.92% | -270.42% | -2,547.24% |
| Normalized Diluted EPS | 37.42% | -404.56% | -212.04% | -135.38% | -26.79% |
| Average Basic Shares Outstanding | 6.35% | 5.29% | 3.78% | 4.29% | 5.04% |
| Average Diluted Shares Outstanding | 6.94% | 0.45% | 4.26% | 7.45% | 8.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |